开能健康科技集团股份有限公司 | 证券代码：300272 | 证券简称：开能健康 | 公告编号：2025-032 | | --- | --- | --- | | 债券代码：123206 | 债券简称：开能转债 | | 关于收购原能集团部分股权暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 本次股权变动前后，公司对原能集团不控制，不并表的投资关系未发生变化， 会计核算上保持以权益法核算，原能集团在公司资产层面自设立以来一直是长期股 权投资，若因未来宏观经济波动、经济周期或短期经营困难等因素导致的公司亏损 的，则存在减值的风险，从而对公司当期损益造成不利影响。敬请广大投资者注意 投资风险。 一、交易概况 1、原能细胞科技集团股份有限公司（以下简称"原能集团"、或"交易标的"） 是开能健康科技集团股份有限公司（以下简称"开能健康"或"公司"）持有 42.4136% 股权的参股公司。基于公司始终坚持"双能驱动"发展战略，在保证净水主业有序 健康快速发展的基础上，公司将不断加大对原能细胞积极探索细胞行业布局的支持。 鉴于公司控股股东、实际控 ...

Group 1: Financial Performance - In 2024, the company achieved total revenue of 1.689 billion yuan, a year-on-year increase of 1.01% [4] - The net profit attributable to shareholders was 84 million yuan, a decrease of 36.90% compared to the previous year; excluding one-time gains and employee stock plan expenses, the net profit was 99 million yuan, reflecting a year-on-year increase of 2.71% [4] - The expected dividend for 2024 is 0.4 yuan per 10 shares, with a total dividend amounting to 90.44 million yuan, representing 108.18% of the annual net profit [3] Group 2: Market Impact and Strategy - Approximately 40% of the company's revenue comes from North America, with the U.S. market accounting for half of that; direct exports from China to the U.S. amount to about 100 million yuan, indicating limited overall impact from U.S. tariffs [1] - The company plans to enhance profit sustainability by optimizing costs, improving operational efficiency, and expanding market reach [2] Group 3: Smart Manufacturing and Innovation - The company aims to introduce more robots, AGVs, and smart detection equipment to improve production efficiency and product quality, while replicating its digital manufacturing experience in overseas factories [2] - The company has achieved industry recognition in smart manufacturing, addressing blind spots across various operational areas through data-driven systems [2] Group 4: Competitive Advantages - The company possesses full-chain production capabilities in the whole-house water purification industry, with over 90% of components produced in-house, allowing for high quality, variety, low cost, and quick response [4] - The company maintains a leading position in comprehensive technical capabilities within the industry, supported by its integrated application technology and specialized component manufacturing [4] Group 5: Industry Growth Potential - The penetration rate of water purification products in China is currently around 23%, compared to over 80% in developed countries, indicating significant growth potential as health awareness and economic capacity increase [5] - The company is well-positioned to capitalize on the expanding market size driven by rising consumer health consciousness [5] Group 6: Risk Management - The company emphasizes its strong competitive capabilities and clear development plans, aiming to deliver solid performance and returns to investors while managing potential market risks [5]

Investment Rating - The investment rating for the company is "Outperform" [1] Core Views - The company's Q1 2025 revenue performance exceeded expectations, with a revenue of 405 million yuan, representing a year-on-year growth of 6% [6] - The decline in net profit for 2024 was primarily due to one-time gains and losses, while the adjusted net profit for 2024 would show a slight increase of 2.71% year-on-year [6] - The overseas business has shown significant growth, with contributions from regions such as the Middle East (62%), Europe (16%), Asia (14%), and North America (5%) [6] - The company's gross margin improved to 39% in 2024, up by 1.47 percentage points, attributed to increased production and enhanced digital management [6] - The company has adjusted its profit forecasts for 2025 and 2026, now expecting net profits of 1.40 billion yuan and 1.70 billion yuan respectively, with a new forecast for 2027 at 1.83 billion yuan [6] Financial Data and Earnings Forecast - Total revenue for 2024 was 1,689 million yuan, with a projected revenue of 1,796 million yuan for 2025, reflecting a growth rate of 6.4% [5] - The net profit for 2024 was 84 million yuan, with an expected increase to 140 million yuan in 2025, indicating a year-on-year growth of 67.8% [5] - The earnings per share (EPS) for 2025 is projected to be 0.24 yuan, with a price-to-earnings (P/E) ratio of 24 [5]

Core Viewpoint - The company, Kaineng Health, reported a modest growth in revenue and net profit for 2024, with a significant improvement in Q1 2025 performance, indicating a positive trend in its financial health and operational efficiency [1][2]. Financial Performance - In 2024, the company achieved a total revenue of 1.689 billion yuan, a year-on-year increase of 1.01% [1] - The net profit attributable to shareholders was 99 million yuan, reflecting a 2.71% increase compared to the previous year [1] - For Q1 2025, the company reported revenue of 405 million yuan, marking a 6.31% year-on-year growth [1] - The net profit for Q1 2025 reached 24.81 million yuan, up 11.30% from the same period last year [1] Innovation and R&D - The company completed 102 R&D projects in 2024, achieving a completion rate of 98% against its plan [2] - It submitted 27 patent applications and received 30 patents, maintaining 296 patents overall [2] - The company developed several innovative technologies, including a modular laser salt level detection and a wireless leak alarm system [2] Digital Transformation - Kaineng Health is advancing its digital transformation by implementing a BI platform that integrates core business data for real-time monitoring and analysis [2][3] - The company has established a digital marketing system focused on enhancing the efficiency of its dealer network [2] Smart Manufacturing - The company was awarded the national "Excellence Level Smart Factory" honor in 2024, reflecting its commitment to smart manufacturing [3] - Automation in production has significantly improved efficiency, with the main valve body output increasing by 25.3% compared to the previous year [3] Strategic Development - The company plans to leverage its "dual energy drive" strategy to capitalize on industry opportunities, focusing on technological advancements and product innovation [4] - In 2025, Kaineng Health aims to enhance product development and management transparency through the implementation of PLM digital tools [4] - The company is also focusing on expanding its international business and enhancing its market insights to develop differentiated competitive strategies [5]

Core Viewpoint - The company, Kaineng Health, has demonstrated robust growth in its operating performance for 2024, driven by strategic initiatives in smart transformation and international expansion, solidifying its competitive edge and industry influence [1]. Financial Performance - In 2024, Kaineng Health achieved a revenue of 1.689 billion yuan, representing a year-on-year growth of 1.01% [2] - The net profit attributable to shareholders reached 83.5757 million yuan, maintaining a leading profitability level in the industry [2] - The company has optimized its product structure and enhanced service efficiency to strengthen its market position amid fierce competition [2]. Technological Innovation - Kaineng Health prioritizes technological innovation as a core driver of development, increasing R&D investment and launching a series of high-efficiency, intelligent water purification products [3] - The company has achieved industry-leading levels in water purification efficiency and water quality safety [3] - Collaborations with top research institutions like Tsinghua University and the Chinese Academy of Sciences have led to significant breakthroughs in key technologies [3]. Smart Transformation - The company has made significant progress in smart transformation by adopting advanced manufacturing technologies, resulting in automation and digitalization of production processes [4] - This transformation has notably improved production efficiency and product quality [4] - Kaineng Health has established a smart management system utilizing big data and cloud computing for precise control across production, sales, and service [4]. International Expansion - Kaineng Health has actively expanded its international presence by participating in international exhibitions and establishing overseas branches [5] - Collaborations with renowned international companies and institutions have advanced the internationalization and standardization of water purification technology [5] - These efforts have enhanced the company's brand recognition and market share globally [5]. Social Responsibility - The company has implemented a share repurchase plan to enhance investor confidence and actively participates in social welfare initiatives [6] - Kaineng Health contributes to societal development through donations and volunteer services [6]. - The company aims to create more value for shareholders and society while pursuing growth in the global health drinking water market [6].

| 证券代码：300272 | 证券简称：开能健康 | 公告编号：2025-021 | | --- | --- | --- | | 债券代码：123206 | 债券简称：开能转债 | | 开能健康科技集团股份有限公司 2024 年度募集资金存放和使用情况专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第2号——上市公司募集 资金管理和使用的监管要求》《深圳证券交易所上市公司自律监管指引第2号— —创业板上市公司规范运作》以及《深圳证券交易所创业板上市公司自律监管指 南第2号——公告格式》的相关规定，现将开能健康科技集团股份公司（以下简 称"公司"）2024年度募集资金存放与实际使用情况报告如下： 一、募集资金基本情况 1、实际募集资金金额、资金到账时间 二、募集资金存放和管理情况 1、募集资金管理制度情况 为规范募集资金管理和使用，提高募集资金使用效率，保护投资者权益，根 据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 ...

2023 年度财务决算报告 开能健康科技集团股份有限公司 2024 年度财务决算报告 开能健康科技集团股份有限公司（以下简称"公司"）2024年度母公司及合并 财务报表及相关报表附注已经天职国际会计师事务所（特殊普通合伙）审计并出 具标准无保留意见的审计报告。 一、基本情况 | 项 目 | 2024 年度 | 2023 年度 | 增减比例 | | --- | --- | --- | --- | | 营业收入（万元） | 168,850.09 | 167,169.94 | 1.01% | | 归属于上市公司股东的净利润（万元） | 8,357.57 | 13,244.67 | -36.90% | | 归属于上市公司股东的扣除非经常性损益的净利润（万 元） | 7,677.45 | 10,475.63 | -26.71% | | 经营活动产生的现金流量净额（万元） | 28,963.93 | 37,483.04 | -22.73% | | 基本每股收益（元） | 0.1476 | 0.2358 | -37.40% | | 稀释每股收益（元） | 0.1444 | 0.2312 | -37.54% | | 加权平均 ...

2024 年度公司内部控制评价报告 开能健康科技集团股份有限公司 2024年度公司内部控制评价报告 开能健康科技集团股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），结合开能健康科技集团股份有限公 司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项监督 的基础上，我们对公司 2024 年 12 月 31 日（内部控制评价报告基准日）的内部 控制有效性进行了自我评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实 ...

开能健康科技集团股份有限公司董事会审计委员会 对会计师事务所2024年度履职情况评估及履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》 《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上市公司自律监 管指引第2号——创业板上市公司规范运作》和《公司章程》等规定和要求，开能健康 科技集团股份有限公司（以下简称"公司"）董事会审计委员会本着勤勉尽责的原则，恪尽 职守，认真履职。现将董事会审计委员会对会计师事务所2024年度履职评估及履行监督职责 的情况汇报如下： 一、2024年年审会计师事务所基本情况 （一）会计师事务所基本信息 机构名称：天职国际会计师事务所（特殊普通合伙）（以下简称"天职国际"） 成立日期：2012年3月5日 组织形式：特殊普通合伙 注册地址：北京市海淀区车公庄西路19号68号楼A-1和A-5区域 首席合伙人：邱靖之 截止2023年12月31日，天职国际合伙人89人，注册会计师1165人，签署过证券服务 业务审计报告的注册会计师414人。 （二）聘任会计师事务所履行的程序 公司第六届董事会审计委员会对天职国际进行了审查，认为天职国际 ...

开能健康科技集团股份有限公司（以下简称"公司"或"开能健康"）于 2025 年 4 月 25 日召开第六届董事会第二十一次会议，审议通过了《关于增加公司 2025 年度向银行等金融机构申请综合授信额度的议案》，具体内容如下： 一、经审批的申请授信额度情况 2024 年 4 月 19 日，公司召开第六届董事会第十四次会议，审议通过了《关 于公司及子公司 2024 年向银行申请授信额度的议案》，公司董事会同意：公司 及纳入合并范围子公司 2024 年度向银行及其他金融机构申请综合授信总额不超 过人民币 18 亿元，授信期限为两年。该事项已经 2024 年 5 月 16 日召开的 2023 年年度股东大会批准实施。 二、拟增加申请授信额度情况 | 证券代码：300272 | 证券简称：开能健康 | 公告编号：2025-023 | | --- | --- | --- | | 债券代码：123206 | 债券简称：开能转债 | | 开能健康科技集团股份有限公司 关于增加公司 2025 年度向银行等金融机构申请授信额度的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏 ...